Abstract
Distribution and glucocorticoid inducibility of lipocortin 1 The glucocorticoids are drugs of enormous therapeutic importance yet, like many other agents in wide clinical use, their precise mechanism(s) of action remain incompletely understood. Because endogenously produced glucocorticoids have important metabolic functions, when administered in "pharmacological" doses for their anti-inflammatory actions this class of drug has many side effects, ranging from the inconvenient to the life-threatening. For The first experiments to demonstrate the existence of the protein were performed independently in three different laboratories each of which showed, in a different in vitro model system, that an anti-inflammatory protein appeared to mediate the suppression by glucocorticoids of phospholipase A2 (PLA2) activity and subsequent eicosanoid synthesis.
These studies stimulated a wave of excitement that this protein, which was named lipocortin, might be "the" mechanism of action of glucocorticoids. This was swiftly followed by a period of disillusionment when a number of groups tried without success to demonstrate anti-inflammatory activity of -the recombinant and native proteins, both in vivo and in vitro.
A major turning point in the rehabilitation of lipocortin 1 into polite, scientific society was the discovery that the recombinant protein required refolding into the correct threedimensional conformation in order to be biologically active.7 Furthermore, it was found that purified lipocortin 1 is readily denatured at airliquid interfaces. As the preparation of solutions for injection or mixtures for incubation nearly always includes at least one bout of vortex mixing, most researchers had therefore been attempting to perform the scientific equi-*valent of hatching chicks from hard boiled eggs - These revelations stimulated the development of powerful new tools with which to examine the actions of lipocortin 1. Firstly, synthetic peptides derived from the primary sequence of the protein and sharing its activity, but possessing enhanced stability and, secondly, antibodies which neutralise lipocortin 1 activity in vivo and in vitro. The use of these tools has allowed clear demonstration of the biological activity of both exogenously administered and endogenously produced lipocortin 1. For example, there is now convincing evidence from various experimental models that exogenous lipocortin 1 and lipocortin 1 peptides mimic, and neutralising antilipocortin 1 antisera abrogate, the suppression by glucocorticoids of several aspects of the inflammatory response including neutrophil migration and the development of oedema and fever.89
Although the lung is rich in lipocortin 1 and has been used in many studies as a source for the isolation of the protein, to date few studies have investigated its biological activity in the respiratory tract. However, neutralising antibodies to lipocortin 1 have been shown to reverse at least one action of glucocorticoid in the lung-namely, the downregulation by dexamethasone of inducible nitric oxide synthase (iNOS) expression in the lung of lipopolysaccharide-treated rats.10 MECHANISM OF ACTION OF LIPOCORTIN 1 Having established that lipocortin 1 possesses anti-inflammatory activity, the next question is obviously "How does it work?" Using a fluorescence activated cell sorter (FACS) and fluorescently tagged antibodies for detecting the protein, it has been shown that lipocortin 1 occupies a specific cell surface binding site on the plasma membrane of the target cell," thus indicating that extracellular release is essential for the activity of this protein ( fig  1) . How this interaction between lipocortin 1 and its binding site triggers a reduction in inflammation is not entirely clear. It is known that in the A549 cell line lipocortin 1 reduces eicosanoid production, not by altering expression of cyclo-oxygenase-2 (COX-2) but by reducing PLA2 activity, perhaps as a result of modulation of signal transduction processes.12
Whether or not this is the case in all cells remains to be determined ( fig 1) .
As in other species, the mechanism of action of lipocortin 1 in the human lung remains to be fully elucidated. Interestingly, an inverse relationship has been shown between the levels of lipocortin 1 and prostaglandin D2 (which can cause bronchoconstriction) in lung lavage fluid from patients with allergic asthma. At the same time this was associated with an increase in the metabolite of prostacyclin (which can protect against bronchoconstriction), giving rise to the intriguing but unproven possibility that lipocortin 1 
